ARVN - Arvinas, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.22
+0.29 (+0.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close33.93
Open33.91
Bid0.00 x 800
Ask35.00 x 1000
Day's Range33.17 - 34.49
52 Week Range15.19 - 61.57
Volume365,112
Avg. Volume661,835
Market Cap1.34B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.23
Earnings DateAug 03, 2020 - Aug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

    NEW HAVEN, Conn., June 29, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

  • GlobeNewswire

    Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

    NEW HAVEN, Conn., June 17, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

  • Here is What Hedge Funds Think About Arvinas, Inc. (ARVN)
    Insider Monkey

    Here is What Hedge Funds Think About Arvinas, Inc. (ARVN)

    In this article you are going to find out whether hedge funds think Arvinas, Inc. (NASDAQ:ARVN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]

  • GlobeNewswire

    Arvinas Appoints Linda Bain to its Board of Directors

    NEW HAVEN, Conn., June 11, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

  • Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why
    Zacks

    Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why

    Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference

    NEW HAVEN, Conn., June 05, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

  • Benzinga

    P/E Ratio Insights for Arvinas

    Looking into the current session, Arvinas Inc. (NASDAQ: ARVN) is trading at $34.69, after a 22.65% drop. Over the past month, the stock decreased by 32.30%, but over the past year, it actually went up by 73.02%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 43.66%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Arvinas Inc. has a lower P/E than the aggregate P/E of 0.7 of the biotechnology industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Friday's Pre-Market Session * Stocks That Hit 52-Week Highs On Wednesday * Recap: Arvinas Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

    Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated data from the dose escalation portion of the company’s Phase 1/2 clinical trial of ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), to be shared as an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting on May 29, 2020. “For ARV-110 to show signs of efficacy in these patients at this early stage of development is strong validation of our PROTAC® technology,” said John Houston, Ph.D., President and Chief Executive Officer at Arvinas.

  • GlobeNewswire

    Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders

    Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that its 2020 Annual Meeting of Stockholders, to be held on Wednesday, June 3, 2020 at 8:30 a.m. Eastern Time, has been changed to a virtual meeting. Stockholders will only be able to participate in this year’s Annual Meeting via the virtual meeting. This change is reflective of the public health impact of the novel coronavirus (COVID-19) outbreak, government restrictions limiting the size of gatherings, and supporting the health and well-being of Arvinas’ stockholders, employees, and communities.

  • Here's Why Arvinas Shares Are Tumbling 13.7% Today
    Motley Fool

    Here's Why Arvinas Shares Are Tumbling 13.7% Today

    Investors were hoping for better initial data from an early-stage trial of its prostate cancer therapy.

  • GlobeNewswire

    Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

    - Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of.

  • How Arvinas (ARVN) Stock Stands Out in a Strong Industry
    Zacks

    How Arvinas (ARVN) Stock Stands Out in a Strong Industry

    Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know
    Zacks

    Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know

    Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Analysts Are Upgrading Arvinas, Inc. (NASDAQ:ARVN) After Its Latest Results
    Simply Wall St.

    Analysts Are Upgrading Arvinas, Inc. (NASDAQ:ARVN) After Its Latest Results

    As you might know, Arvinas, Inc. (NASDAQ:ARVN) just kicked off its latest first-quarter results with some very strong...

  • Benzinga

    Recap: Arvinas Q1 Earnings

    Shares of Arvinas (NASDAQ:ARVN) rose 1.5% after the company reported Q1 results.Quarterly Results Earnings per share were down 21.74% over the past year to ($0.56), which beat the estimate of ($0.60).Revenue of $6,240,000 up by 55.38% from the same period last year, which beat the estimate of $4,500,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.View more earnings on ARVNRevenue guidance hasn't been issued by the company for now.Price Action 52-week high: $57.1352-week low: $15.19Price action over last quarter: Up 39.17%Company Overview Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.See more from Benzinga * Stocks That Hit 52-Week Highs On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update

    NEW HAVEN, Conn., April 28, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

  • Were Hedge Funds Right About Arvinas, Inc. (ARVN)?
    Insider Monkey

    Were Hedge Funds Right About Arvinas, Inc. (ARVN)?

    Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • GlobeNewswire

    Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

    Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business continuity, including clinical trials, supply chain, and discovery research. Throughout the ongoing COVID-19 pandemic, Arvinas remains committed to keeping employees and their families safe and to reduce the number of people exposed to the virus. Arvinas also remains committed to continuing to create a new class of drugs based on targeted protein degradation, including continued development of the company’s PROTAC® protein degraders currently in ongoing clinical trials.

  • GlobeNewswire

    Arvinas to Present at the American Society of Clinical Oncology Annual Meeting

    Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the acceptance of an abstract for presentation at the American Society of Clinical Oncology (ASCO) annual meeting being held virtually May 29 - June 2, 2020. ARV-110 is one of Arvinas’ two clinical-stage PROTAC® protein degraders and is being developed for the treatment of men with metastatic castration-resistant prostate cancer. The second is ARV-471, which is in a Phase 1 dose escalation trial for patients with locally advanced or metastatic ER+/HER2- breast cancer.

  • The Arvinas, Inc. (NASDAQ:ARVN) Analysts Have Been Trimming Their Sales Forecasts
    Simply Wall St.

    The Arvinas, Inc. (NASDAQ:ARVN) Analysts Have Been Trimming Their Sales Forecasts

    The analysts covering Arvinas, Inc. (NASDAQ:ARVN) delivered a dose of negativity to shareholders today, by making a...

  • Is Arvinas (NASDAQ:ARVN) A Risky Investment?
    Simply Wall St.

    Is Arvinas (NASDAQ:ARVN) A Risky Investment?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

  • GlobeNewswire

    Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    NEW HAVEN, Conn., March 16, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

  • What's in the Offing for Emerson (EMR) in Q1 Earnings?
    Zacks

    What's in the Offing for Emerson (EMR) in Q1 Earnings?

    Emerson's (EMR) fiscal Q1 earnings are likely to have gained from steady demand in process and hybrid end markets. Weak global discrete manufacturing market might have been a concern.

  • Will Arvinas Continue to Surge Higher?
    Zacks

    Will Arvinas Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Arvinas.

  • Shareholders Are Thrilled That The Arvinas (NASDAQ:ARVN) Share Price Increased 208%
    Simply Wall St.

    Shareholders Are Thrilled That The Arvinas (NASDAQ:ARVN) Share Price Increased 208%

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...